Guggenheim 3rd Annual Healthcare Innovation Conference - PHARVARIS NV

Based on the transcript provided, here is the extraction of forward-looking statements:

• Explicit Guidance:

  • NDA Submission (Prophylaxis): Targeting submission for Ducritaban XR (prophylactic) in the first half of 2027, contingent on the collection of Phase 4 long-term safety data expected by that time.
  • NDA Submission (On-Demand): Pivotal Phase 3 on-demand data readout already reported; NDA submission date set for April 23, 2027, for on-demand treatment of HAE attacks.
  • CREATE Study (Acquired Angioedema): Top-line data from the CREATE study (Ducritaban for prevention of Acquired Angioedema attacks) expected in the first quarter of next year (2026).
  • MAA Status: Marketing Authorization Application (MAA) for international markets is currently validated and under review.
  • Commercial Launch Timeline: Targeting U.S. market approval and strong launch next year (2027).

• Business-Segment Outlook:

  • Market Structure Prediction (On-Demand): Anticipates oral products will dominate the on-demand segment due to convenience and discrete administration over injectables; believes Ducritaban's same mechanism as Icatibut (B2 receptor antagonist) positions it to capture this shift.
  • Market Structure Prediction (Prophylaxis): Expects a bifurcated market where a winner will emerge in both oral and injectable spaces, allowing patient/physician preference to dictate choice without sacrificing efficacy for convenience.
  • Commercial Team Buildout: Targeting 80–90% hiring completion for the U.S. commercial team (approx. 30–40 sales reps) with a focus on reaching ~2,500 key specialists (allergists/physicians).
  • Portfolio Strategy: Leveraging both on-demand and prophylactic options to maximize portfolio value holistically rather than optimizing a single asset in isolation.

• Market and Competitive Outlook:

  • Competitive Landscape: Views the on-demand field as highly competitive but believes the shift to oral delivery is the primary trend.
  • Switching Opportunities: Aiming to capture patients currently on Orladeo (noting a ~47% response rate for Orladeo) and those dissatisfied with injectable therapies (e.g., Turocero/Herceptin context implied via "injection site issues") or those seeking better efficacy than current oral prophylaxis.
  • Pricing Strategy: Plans to navigate within existing "pricing corridors" (citing Ectorally at ~$17,800/dose) but aims for creative structuring to ensure rapid patient access; specific pricing levels not yet finalized but expected to remain compelling.
  • Differentiation Focus: Positioning Ducritaban against competitors (specifically referencing "Ectery" likely referring to Turocero/Conakly or similar) on the "single-dose resolution" metric (83% vs. ~38–39% for competitors requiring second doses).

• Macro / Industry Outlook:

  • Disease Prevalence (DANZOL): Notes a significant shift in global treatment patterns; <5% of U.S. patients currently on danazol (vs. 20–30% in international markets like Latin America/Asia), indicating a strong U.S. demand for modern therapies.
  • Unmet Need (AAE): Highlights a critical lack of treatment options for Bradykinin-mediated Angioedema (AAE) in the general community, creating a "strong desire" for available treatments that could justify priority review.
  • Safety Concerns: Anticipates FDA scrutiny regarding liver enzyme elevations but predicts acceptance given the background fragility of HAE livers (C1s deficiency) and the "clean" cardiovascular/GI safety profile compared to other orals.

• Strategic Initiatives:

  • Label Expansion Strategy: Aiming for a broader label covering "bradykinin-mediated angioedema" (combining HAE and AAE data) to potentially trigger Priority Review status.
  • Label Differentiation: Seeking regulatory inclusion of three specific differentiators: rapid onset of action (1.28 hours or end of progression), complete symptom resolution (<12 hours), and single-dose durability (83% of patients).
  • Geographic Expansion: Prioritizing U.S. launch first, with Japan and European countries identified as potential next markets for international expansion; XUS (non-U.S.) strategy (partner vs. internal) is currently undetermined and under discussion.
  • Access Programs: Planning for "quick start sampling" and creative contracting strategies to facilitate rapid patient access post-approval.

• Risks and Headwinds to Outlook:

  • Regulatory Timing: NDA filing timing is dependent on the completion of Phase 4 open-label extension safety data; any delays in data collection could push the submission past the H1 2027 target.
  • Label Negotiations: Final label content depends on successful discussions with regulators regarding specific endpoints (rapid onset, single-dose resolution).
  • Competitive Response: Acknowledges a "highly competitive field" and the need to prove oral efficacy matches injectable standards to gain market share.
  • XUS Execution Risk: No committed strategy for international launch (partnering vs. self-reliance), presenting potential delays or execution complexity outside the U.S.

• Management Tone on the Future:

  • Confidence Level: High confidence in the "injectable-like efficacy" of the oral product and the inevitability of the market shift toward oral on-demand therapies.
  • Urgency: Emphasizes the "strong desire" of the AAE patient community to receive treatment, driving the parallel submission strategy.
  • Strategic Flexibility: Maintains a flexible approach to international commercialization (XUS) and pricing to maximize access and value, avoiding rigid commitment until post-approval.
  • Safety Reassurance: Repeatedly emphasizes the "well-tolerated" profile and the specific context of liver enzyme findings to preempt regulatory hesitation.

• Miscellaneous:

  • Molecular Formulation: Ducritaban has two formulations: one for upper GI absorption (on-demand) and one prophylactic formulation; both share the same mechanism of action.
  • Target Population: Focus on HAE patients and the subset of Bradykinin-mediated Angioedema (AAE) patients who currently have no treatment options.
  • Peer Feedback: Initial interactions with U.S. peers regarding the 83% single-dose resolution rate have been "very positive," particularly regarding economic implications for payers.